Dainippon's Phase III Trial Shows Lurasidone Advantage Over Placebo, But Not Against Zyprexa
This article was originally published in The Pink Sheet Daily
Executive Summary
Like the newly-approved Saphris, lurasidone showed little impact on weight and other metabolic parameters in second Phase III PEARL study. The Japanese firm is going for a safety, not efficacy, entry point into the atypical class.
You may also be interested in...
Dainippon Sumitomo Awakes To U.S. Market - Buys Sepracor For $2.6 Billion
With an eye toward U.S. market expansion, Dainippon Sumitomo Pharma will buy Sepracor for $2.6 billion, a deal that gives the Japanese drug maker a portfolio of marketed and pipeline medicines, as well as an experienced regulatory and commercial organization
Dainippon Sumitomo Awakes To U.S. Market - Buys Sepracor For $2.6 Billion
With an eye toward U.S. market expansion, Dainippon Sumitomo Pharma will buy Sepracor for $2.6 billion, a deal that gives the Japanese drug maker a portfolio of marketed and pipeline medicines, as well as an experienced regulatory and commercial organization
Dainippon Sumitomo Awakes To The U.S. Market And Buys Sepracor For $2.6 Billion
With an eye toward U.S. market expansion, Dainippon Sumitomo Pharma will buy Sepracor for $2.6 billion, a deal that gives the Japanese drug maker a portfolio of marketed and pipeline medicines, as well as an experienced regulatory and commercial organization